PMV Pharmaceuticals

PMVP Lead: Phase 2 4 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-06

Catalyst timeline

Rezatapopt topline4Q 2026Rezatapopt topline, 4Q 2026, thesis-defining
Rezatapopt NDA filing1Q 2027Rezatapopt NDA filing, 1Q 2027, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (7 active programs)

rezatapopt

PC14586

Small Molecule Target: p53 Y220C, p53, TP53 Y220C

Ovarian Cancer Phase 2 Phase 1/2 trial oral NCT04585750
Non-Small Cell Lung Cancer Phase 2 oral NCT04585750
Breast Cancer Phase 2 oral NCT04585750
Endometrial Cancer Phase 2 oral NCT04585750
Colorectal Cancer Phase 2 oral NCT04585750
Pancreatic Cancer Phase 2 oral
Solid Tumors Phase 2 NCT04585750

Technology platforms

Precision Oncology Platform

Small molecule discovery and development platform targeting p53 mutations and p53-related cancers; leverages structural biology, assays, and biomarkers to identify and optimize selective small molecules that structurally correct specific mutant p53 proteins to restore wild-type function; disease focus is tumor-agnostic oncology defined by p53 genomic alterations.

Targets: p53

Biotech Distilled coverage (4)

2026-08-15 UPDATE: PMV Pharma (PMVP) - The Going Concern Flag Goes Up 🔒 Paid
2026-05-12 UPDATE: PMV Pharma (PMVP) - The ORR Shrinks, The NEJM Validates, The Clock Tightens
2026-03-08 UPDATE: PMV Pharma (PMVP) - The Data Gets Stronger... 🔒 Paid
2026-02-16 PMV Pharmaceuticals (PMVP): Scientific Deep Dive for Rezatapopt 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.